Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

95.16 +0.20 (+0.21%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a...

Via MarketMinute

Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections

September 19, 2025

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol

September 18, 2025

From AstraZeneca

Via Business Wire

AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial ↗

September 17, 2025

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and consistent safety profiles.

Via Benzinga

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

Via Investor Brand Network

Topics Artificial Intelligence Intellectual Property

AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease ↗

September 17, 2025

Via Stocktwits

Retail Buzz Builds As AstraZeneca’s Tagrisso Combo Extends Lung Cancer Survival To Nearly 4 Years ↗

September 07, 2025

Via Stocktwits

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence Intellectual Property

SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis

September 17, 2025

From AstraZeneca

Via Business Wire

GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America ↗

September 16, 2025

The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.

Via Stocktwits

Topics Artificial Intelligence Government World Trade

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit ↗

September 15, 2025

AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows.

Via Benzinga

Topics Government

The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health

September 15, 2025

The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor...

Via MarketMinute

Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs ↗

September 12, 2025

Pharmaceutical companies are pulling investment from the UK as NHS drug spending falls and pricing disputes worsen.

Via Benzinga

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer ↗

September 10, 2025

The FDA approved AstraZeneca's Koselugo for children 1+ with NF1 and inoperable nerve tumors, expanding treatment options with an established safe dose.

Via Benzinga

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗

September 09, 2025

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential...

Via Benzinga

Topics ETFs Government

AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study ↗

September 08, 2025

AstraZeneca's Tagrisso with chemotherapy improved survival in advanced NSCLC, extending median overall survival by nearly 10 months over monotherapy.

Via Benzinga

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗

September 08, 2025

The company is working on a treatment for an autoimmune disease that affects the muscles.

Via Investor's Business Daily

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗

September 07, 2025

Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.

Via The Motley Fool

TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer

September 07, 2025

From AstraZeneca

Via Business Wire

AstraZeneca, Corning And More On CNBC's 'Final Trades' ↗

September 04, 2025

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his

Via Benzinga

Market Jitters: Wall Street Braces for Continued Volatility

September 02, 2025

The U.S. stock market is once again sending signals of caution, as major indices experienced a notable pullback from their recent record highs in early September 2025. This downturn, following a robust...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure ↗

September 02, 2025

AstraZeneca's Baxdrostat met all endpoints in a Phase 3 trial, showing sustained blood pressure reductions in patients with resistant hypertension.

Via Benzinga

Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial

August 30, 2025

From AstraZeneca

Via Business Wire

AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results ↗

August 30, 2025

AstraZeneca, on Saturday, unveiled promising results for a new hypertension treatment that aims to help the roughly 650,000 people.

Via Investor's Business Daily

Looking Into AstraZeneca's Recent Short Interest ↗

August 29, 2025

Via Benzinga

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

August 26, 2025

As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data ↗

August 26, 2025

Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026.

Via Benzinga

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up ↗

August 25, 2025

BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.